1167 Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.06 |
52 Week High | HK$9.89 |
52 Week Low | HK$1.81 |
Beta | 0.68 |
11 Month Change | -18.25% |
3 Month Change | -39.41% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -75.74% |
Recent News & Updates
Recent updates
Shareholder Returns
1167 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -16.3% | 18.1% | 13.0% |
1Y | n/a | -1.6% | 16.1% |
Return vs Industry: Insufficient data to determine how 1167 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 1167 performed against the Hong Kong Market.
Price Volatility
1167 volatility | |
---|---|
1167 Average Weekly Movement | 11.4% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 7.1% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1167's share price has been volatile over the past 3 months.
Volatility Over Time: 1167's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 300 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company’s lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
1167 fundamental statistics | |
---|---|
Market cap | HK$1.63b |
Earnings (TTM) | -HK$445.97m |
Revenue (TTM) | HK$88.47m |
14.7x
P/S Ratio-2.9x
P/E RatioIs 1167 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1167 income statement (TTM) | |
---|---|
Revenue | CN¥81.39m |
Cost of Revenue | CN¥75.19m |
Gross Profit | CN¥6.20m |
Other Expenses | CN¥416.52m |
Earnings | -CN¥410.32m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.52 |
Gross Margin | 7.62% |
Net Profit Margin | -504.11% |
Debt/Equity Ratio | 4.8% |
How did 1167 perform over the long term?
See historical performance and comparison